Revenue
$2.05M
Fiscal year ended 2025-12-31Operating income
-$3.33M
Fiscal year ended 2025-12-31Free cash flow
Unavailable
Fiscal year ended 2025-12-3120/20 Biolabs, Inc. (AIDX) reported revenue of $2.05M and net income of -$3.74M for the fiscal year ended 2025-12-31. This page shows 2 annual periods of income statement, balance sheet and cash flow figures normalized from 20/20 Biolabs, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Testing Laboratories.
Income
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $2.05M | $1.75M |
| Cost of revenue | $1.44M | $1.39M |
| Gross profit | $604.54K | $360.31K |
| Operating income | -$3.33M | -$5.68M |
| Net income | -$3.74M | -$5.55M |
| Research & development | $592.57K | $1.26M |
| Weighted-average diluted shares | shares 4.93M | shares 4.80M |
| Pretax income | Unavailable | Unavailable |
| Income tax expense | Unavailable | Unavailable |
| Diluted EPS | $-0.76 | $-1.16 |
| Selling, general & administrative | $3.34M | $4.76M |
| General & administrative | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Cash & equivalents | $1.03M | $1.78M |
| Total assets | $4.14M | $3.58M |
| Current assets | $1.47M | $2.03M |
| Total liabilities | $4.16M | $2.08M |
| Current liabilities | $2.46M | $1.36M |
| Total equity incl. NCI | -$19.22K | $1.51M |
| Temporary (mezzanine) equity | Unavailable | Unavailable |
| Inventory | $116.22K | $47.16K |
| Accounts receivable | $199.95K | $135.27K |
| Goodwill | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable |
| Accounts payable | $868.54K | $372.30K |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Operating cash flow | -$1.92M | -$2.60M |
| Capital expenditures | Unavailable | Unavailable |
| Investing cash flow | Unavailable | Unavailable |
| Financing cash flow | $1.16M | $293.33K |
| Net change in cash | -$758.02K | -$2.31M |
| Stock-based compensation | $516.18K | $2.18M |
| Common dividends paid | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable |
| Depreciation & amortization | $63.26K | $116.04K |
Derived
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Free cash flow | Unavailable | Unavailable |
| Gross margin | 29.6% | 20.6% |
| Operating margin | -162.9% | -324.0% |
| FCF margin | Unavailable | Unavailable |
| SBC / revenue | 25.2% | 124.2% |
| Current ratio | 0.60x | 1.50x |
| Revenue YoY growth | 16.7% | Unavailable |
| Net margin | -182.8% | -316.8% |
| R&D / revenue | 29.0% | 72.0% |
| CapEx / revenue | Unavailable | Unavailable |
| Long-term debt / equity | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AIDX in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-20View SEC filing
10-K · Filed 2026-03-31View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.